Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib
A subset of patients with differentiated thyroid carcinoma develop radioiodine refractory (RAIR) incurable disease, which typically has a poor prognosis. The multitargeted tyrosine kinase inhibitor lenvatinib has demonstrated significant improvements in progression-free survival in RAIR thyroid canc...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Case Reports in Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2023/8841696 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832546798143537152 |
|---|---|
| author | Vineeth Sukrithan Lisa Kim Jennifer A. Sipos Ashima Goyal Ye Zhou Daniel Addison Manisha Shah Bhavana Konda Ajay Vallakati |
| author_facet | Vineeth Sukrithan Lisa Kim Jennifer A. Sipos Ashima Goyal Ye Zhou Daniel Addison Manisha Shah Bhavana Konda Ajay Vallakati |
| author_sort | Vineeth Sukrithan |
| collection | DOAJ |
| description | A subset of patients with differentiated thyroid carcinoma develop radioiodine refractory (RAIR) incurable disease, which typically has a poor prognosis. The multitargeted tyrosine kinase inhibitor lenvatinib has demonstrated significant improvements in progression-free survival in RAIR thyroid cancers compared to placebos. However, in the phase III SELECT trial of the drug in thyroid cancer, 5.4% of patients on lenvatinib experienced arterial thromboembolic events, with 2.7% experiencing severe grade ≥3 toxicities associated with arterial vascular events. This case study reports a patient with metastatic poorly differentiated follicular thyroid cancer who developed significant obstructive coronary artery disease following initiation of lenvatinib treatment, despite no predisposing cardiovascular risk factors apart from a remote smoking history. The possibility of developing coronary or peripheral artery disease should be considered in patients who are on targeted therapies, such as lenvatinib, even in the absence of traditional cardiovascular risk factors. In addition, baseline cardiac risk assessment and early treatment should be pursued to minimize interruptions to potentially lifesaving cancer therapy. |
| format | Article |
| id | doaj-art-4337e1f4ed4b4dcfab351e697d0c32a1 |
| institution | Kabale University |
| issn | 2090-651X |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Endocrinology |
| spelling | doaj-art-4337e1f4ed4b4dcfab351e697d0c32a12025-02-03T06:47:14ZengWileyCase Reports in Endocrinology2090-651X2023-01-01202310.1155/2023/8841696Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor LenvatinibVineeth Sukrithan0Lisa Kim1Jennifer A. Sipos2Ashima Goyal3Ye Zhou4Daniel Addison5Manisha Shah6Bhavana Konda7Ajay Vallakati8Department of Internal MedicineDepartment of Internal MedicineDepartment of Internal MedicineDepartment of Internal MedicineDepartment of Internal MedicineDepartment of Internal MedicineDepartment of Internal MedicineDepartment of Internal MedicineDepartment of Internal MedicineA subset of patients with differentiated thyroid carcinoma develop radioiodine refractory (RAIR) incurable disease, which typically has a poor prognosis. The multitargeted tyrosine kinase inhibitor lenvatinib has demonstrated significant improvements in progression-free survival in RAIR thyroid cancers compared to placebos. However, in the phase III SELECT trial of the drug in thyroid cancer, 5.4% of patients on lenvatinib experienced arterial thromboembolic events, with 2.7% experiencing severe grade ≥3 toxicities associated with arterial vascular events. This case study reports a patient with metastatic poorly differentiated follicular thyroid cancer who developed significant obstructive coronary artery disease following initiation of lenvatinib treatment, despite no predisposing cardiovascular risk factors apart from a remote smoking history. The possibility of developing coronary or peripheral artery disease should be considered in patients who are on targeted therapies, such as lenvatinib, even in the absence of traditional cardiovascular risk factors. In addition, baseline cardiac risk assessment and early treatment should be pursued to minimize interruptions to potentially lifesaving cancer therapy.http://dx.doi.org/10.1155/2023/8841696 |
| spellingShingle | Vineeth Sukrithan Lisa Kim Jennifer A. Sipos Ashima Goyal Ye Zhou Daniel Addison Manisha Shah Bhavana Konda Ajay Vallakati Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib Case Reports in Endocrinology |
| title | Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib |
| title_full | Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib |
| title_fullStr | Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib |
| title_full_unstemmed | Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib |
| title_short | Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib |
| title_sort | coronary artery and peripheral vascular disease in a patient with poorly differentiated thyroid cancer treated with the tyrosine kinase inhibitor lenvatinib |
| url | http://dx.doi.org/10.1155/2023/8841696 |
| work_keys_str_mv | AT vineethsukrithan coronaryarteryandperipheralvasculardiseaseinapatientwithpoorlydifferentiatedthyroidcancertreatedwiththetyrosinekinaseinhibitorlenvatinib AT lisakim coronaryarteryandperipheralvasculardiseaseinapatientwithpoorlydifferentiatedthyroidcancertreatedwiththetyrosinekinaseinhibitorlenvatinib AT jenniferasipos coronaryarteryandperipheralvasculardiseaseinapatientwithpoorlydifferentiatedthyroidcancertreatedwiththetyrosinekinaseinhibitorlenvatinib AT ashimagoyal coronaryarteryandperipheralvasculardiseaseinapatientwithpoorlydifferentiatedthyroidcancertreatedwiththetyrosinekinaseinhibitorlenvatinib AT yezhou coronaryarteryandperipheralvasculardiseaseinapatientwithpoorlydifferentiatedthyroidcancertreatedwiththetyrosinekinaseinhibitorlenvatinib AT danieladdison coronaryarteryandperipheralvasculardiseaseinapatientwithpoorlydifferentiatedthyroidcancertreatedwiththetyrosinekinaseinhibitorlenvatinib AT manishashah coronaryarteryandperipheralvasculardiseaseinapatientwithpoorlydifferentiatedthyroidcancertreatedwiththetyrosinekinaseinhibitorlenvatinib AT bhavanakonda coronaryarteryandperipheralvasculardiseaseinapatientwithpoorlydifferentiatedthyroidcancertreatedwiththetyrosinekinaseinhibitorlenvatinib AT ajayvallakati coronaryarteryandperipheralvasculardiseaseinapatientwithpoorlydifferentiatedthyroidcancertreatedwiththetyrosinekinaseinhibitorlenvatinib |